S. Helms, C. Müller, and N. Melzer, “Tocilizumab-Induced Limbic Encephalitis: Another Adverse Effect of Disrupted IL-6 Signalling?”, acmcr, vol. 5, no. 5, pp. 704–709, Oct. 2021.